Fenofibrate / simvastatin benefit in dyslipidemia explored

Fenofibrate/Simvastatin benefit in dyslipidemia explored
Combination treatment with fenofibrate and simvastatin significantly reduces postprandial triglyceride levels compared with simvastatin alone in all subjects, regardless of fasting triglyceride level, but reduces atherogenic apolipoprotein B48 particles only in those with increased fasting triglyceride levels, according to research published online Oct. 25 in Diabetes Care.

(HealthDay)—Combination treatment with fenofibrate and simvastatin (FENO-S) significantly reduces postprandial (PP) triglyceride (TG) levels compared with simvastatin alone in all subjects, regardless of fasting TG level, but reduces atherogenic apolipoprotein (apo) B48 particles only in those with increased fasting TG levels, according to research published online Oct. 25 in Diabetes Care.

Gissette Reyes-Soffer, M.D., of the Columbia University Medical Center in New York City, and colleagues conducted a study involving a subset of 139 subjects (mean age, 61 years) from the Action to Control in Diabetes lipid study (ACCORD Lipid) to evaluate the effect of combination therapy with FENO-S compared with placebo plus (PL-S) on PP lipid and lipoprotein levels. Primary measures included PP plasma TG, apoB48, and apoCIII, measured over 10 hours after an oral fat load.

The researchers found that the PP TG incremental area under the curve (IAUC) above fasting was 572 and 770 in the FENO-S and PL-S groups, respectively (P = 0.008). In the FENO-S versus the PL-S group, there was a significant reduction in PP apoB48 IAUC. On the day of the study, fasting TG levels correlated with PP TG IAUC for both FENO-S and PL-S groups. For PP TG IAUC, the fibrate effect was constant across the range of fasting TG levels, while for PP apoB48 IAUC, the reduction was only seen when fasting TG levels were increased.

"These results may have implications for interpretation of the overall ACCORD Lipid trial, which suggested benefit from FENO-S only in dyslipidemic individuals," the authors write.

One author disclosed to and Merck Pharmaceuticals, both of which provided the study medications for the ACCORD Lipid trial.


Explore further

The Homburg Cream and Sugar study

More information: Abstract
Full Text (subscription or payment may be required)
Journal information: Diabetes Care

Copyright © 2012 HealthDay. All rights reserved.

Citation: Fenofibrate / simvastatin benefit in dyslipidemia explored (2012, November 1) retrieved 23 September 2019 from https://medicalxpress.com/news/2012-11-fenofibrate-simvastatin-benefit-dyslipidemia-explored.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more